Skip to main content

Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease.

Publication ,  Journal Article
Mosher, CL; Nanna, MG; Jawitz, OK; Raman, V; Farrow, NE; Aleem, S; Casaburi, R; MacIntyre, NR; Palmer, SM; Myers, ER
Published in: JAMA Netw Open
June 1, 2022

IMPORTANCE: Pulmonary rehabilitation (PR) after exacerbation of chronic obstructive pulmonary disease (COPD) is effective in reducing COPD hospitalizations and mortality while improving health-related quality of life, yet use of PR remains low. Estimates of the cost-effectiveness of PR in this setting could inform policies to improve uptake. OBJECTIVE: To estimate the cost-effectiveness of participation in PR after hospitalization for COPD. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation estimated the cost-effectiveness of participation in PR compared with no PR after COPD hospitalization in the US using a societal perspective analysis. A Markov microsimulation model was developed to estimate the cost-effectiveness in the US health care system with a lifetime horizon, 1-year cycle length, and a discounted rate of 3% per year for both costs and outcomes. Data sources included published literature from October 1, 2001, to April 1, 2021, with the primary source being an analysis of Medicare beneficiaries living with COPD between January 1, 2014, and December 31, 2015. The analysis was designed and conducted from October 1, 2019, to December 15, 2021. A base case microsimulation, univariate analyses, and a probabilistic sensitivity analysis were performed. INTERVENTIONS: Pulmonary rehabilitation compared with no PR after COPD hospitalization. MAIN OUTCOMES AND MEASURES: Net cost in US dollars, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio. RESULTS: Among the hypothetical cohort with a mean age of 76.9 (age range, 60-92) years and 58.6% women, the base case microsimulation from a societal perspective demonstrated that PR resulted in net cost savings per patient of $5721 (95% prediction interval, $3307-$8388) and improved quality-adjusted life expectancy (QALE) (gain of 0.53 [95% prediction interval, 0.43-0.63] years). The findings of net cost savings and improved QALE with PR did not change in univariate analyses of patient age, the Global Initiative for Obstructive Lung Disease stage, or number of PR sessions. In a probabilistic sensitivity analysis, PR resulted in net cost savings and improved QALE in every one of 1000 samples and was the dominant strategy in 100% of simulations at any willingness-to-pay threshold. In a 1-way sensitivity analysis of total cost, assuming completion of 36 sessions, a single PR session would remain cost saving to $171 per session and had an incremental cost-effectiveness ratio of $884 per session for $50 000/QALY and $1597 per session for $100 000/QALY. CONCLUSIONS AND RELEVANCE: In this economic evaluation, PR after COPD hospitalization appeared to result in net cost savings along with improvement in QALE. These findings suggest that stakeholders should identify policies to increase access and adherence to PR for patients with COPD.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Netw Open

DOI

EISSN

2574-3805

Publication Date

June 1, 2022

Volume

5

Issue

6

Start / End Page

e2218189

Location

United States

Related Subject Headings

  • United States
  • Quality-Adjusted Life Years
  • Quality of Life
  • Pulmonary Disease, Chronic Obstructive
  • Middle Aged
  • Medicare
  • Male
  • Humans
  • Female
  • Cost-Benefit Analysis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mosher, C. L., Nanna, M. G., Jawitz, O. K., Raman, V., Farrow, N. E., Aleem, S., … Myers, E. R. (2022). Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease. JAMA Netw Open, 5(6), e2218189. https://doi.org/10.1001/jamanetworkopen.2022.18189
Mosher, Christopher L., Michael G. Nanna, Oliver K. Jawitz, Vignesh Raman, Norma E. Farrow, Samia Aleem, Richard Casaburi, Neil R. MacIntyre, Scott M. Palmer, and Evan R. Myers. “Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease.JAMA Netw Open 5, no. 6 (June 1, 2022): e2218189. https://doi.org/10.1001/jamanetworkopen.2022.18189.
Mosher CL, Nanna MG, Jawitz OK, Raman V, Farrow NE, Aleem S, et al. Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease. JAMA Netw Open. 2022 Jun 1;5(6):e2218189.
Mosher, Christopher L., et al. “Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease.JAMA Netw Open, vol. 5, no. 6, June 2022, p. e2218189. Pubmed, doi:10.1001/jamanetworkopen.2022.18189.
Mosher CL, Nanna MG, Jawitz OK, Raman V, Farrow NE, Aleem S, Casaburi R, MacIntyre NR, Palmer SM, Myers ER. Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease. JAMA Netw Open. 2022 Jun 1;5(6):e2218189.

Published In

JAMA Netw Open

DOI

EISSN

2574-3805

Publication Date

June 1, 2022

Volume

5

Issue

6

Start / End Page

e2218189

Location

United States

Related Subject Headings

  • United States
  • Quality-Adjusted Life Years
  • Quality of Life
  • Pulmonary Disease, Chronic Obstructive
  • Middle Aged
  • Medicare
  • Male
  • Humans
  • Female
  • Cost-Benefit Analysis